159974-63-7

Usage

Uses

Used in Pharmaceutical Industry:
2-PIPERAZIN-1-YL-BENZOIC ACID METHYL ESTER is used as a building block for the synthesis of drug molecules due to its potential therapeutic properties and diverse pharmacological activities.
Used in Antipsychotic Applications:
2-PIPERAZIN-1-YL-BENZOIC ACID METHYL ESTER is used as an antipsychotic agent, being investigated for its potential to treat various psychiatric disorders.
Used in Antihistamine Applications:
2-PIPERAZIN-1-YL-BENZOIC ACID METHYL ESTER is used as an antihistamine agent, being explored for its potential to alleviate allergic reactions and symptoms.
Used in Antidepressant Applications:
2-PIPERAZIN-1-YL-BENZOIC ACID METHYL ESTER is used as a selective serotonin reuptake inhibitor (SSRI), being studied for its potential to treat depression and anxiety disorders by modulating serotonin levels in the brain.
Used in Anti-inflammatory Applications:
2-PIPERAZIN-1-YL-BENZOIC ACID METHYL ESTER is used as an anti-inflammatory agent, being explored for its potential to reduce inflammation and associated symptoms.
Used in Anti-cancer Applications:
2-PIPERAZIN-1-YL-BENZOIC ACID METHYL ESTER is used as a potential anti-cancer agent, being investigated for its ability to inhibit cancer cell growth and proliferation, making it a valuable compound for drug discovery and development in oncology.

InChI:InChI=1/C12H16N2O2/c1-16-12(15)10-4-2-3-5-11(10)14-8-6-13-7-9-14/h2-5,13H,6-9H2,1H3

Upstream product

• 67-56-1 methanol 
• 446831-27-2 2-(piperazin-1-yl)benzoic acid 
• 110-85-0 piperazine 
• 610-94-6 2-bromobenzoic acid methyl ester 
• 584-08-7 potassium carbonate 
• 159974-40-0 2-[2-(2-Oxo-oxazolidin-3-yl)-ethylamino]-benzoic acid methyl ester 

Downstream Products

• 179480-81-0 4-(2-aminocarbonylphenyl)piperazine 
• 1253382-56-7 2-{4-[2-(3,5-dimethyl-pyrazol-1-yl)-acetyl]-piperazin-1-yl}-benzoic acid methyl ester 
• 1253382-59-0 N-(2-amino-phenyl)-2-{4-[2-(3,5-dimethyl-pyrazol-1-yl)-acetyl]-piperazin-1-yl}-benzamide 
• 1253936-85-4 1-{4-[2-(1H-benzoimidazol-2-yl)phenyl]piperazin-1-yl}-2-(3,5-dimethyl-pyrazol-1-yl)ethanone 
• 1253382-55-6 2-{4-[2-(3,5-dimethyl-pyrazol-1-yl)-acetyl]-piperazin-1-yl}-N-pyridin-4-yl-benzamide 
• 1253382-57-8 2-{4-[2-(3,5-dimethyl-pyrazol-1-yl)-acetyl]-piperazin-1-yl}-benzoic acid 
• 1227170-16-2 methyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)benzoate 
• 446831-27-2 2-(piperazin-1-yl)benzoic acid 

Relevant academic research and scientific papers

CXCR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

CXCR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising the

A versatile and practical microwave-assisted synthesis of sterically hindered N-arylpiperazines

A wide-ranging and practical synthesis of structurally diverse, sterically hindered N-arylpiperazines from 2,2′-(4-nitrophenylsulfonylazanediyl) bis(ethane-2,1-diyl) bis(4-nitrobenzenesulfonate) and substituted anilines has been achieved using microwave i

MORPHOLINONE AND MORPHOLINE DERIVATIVES AND USES THEREOF

This invention is directed to morpholinone and morpholine derivatives which are selective antagonists for human α 1a receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the α 1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Oxazolidinones as alpha 1A receptor antagonists

This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Use of 2-Oxazolidinones As Latent Aziridine Equivalents. III. Preparation of N-Substituted Piperazines.

A number of N-aryl and N-alkyl substituted piperazines 1 were prepared from variously substituted 2-oxazolidinone derivatives 3.The method involved treatment of 3 with HBr in glacial acetic acid followed by heating the resulting ring-opened salts 5 in alcoholic solvent.The piperazines 1a-1q were isolated by crystallization in yields ranging from 23-91percent.